MNPR

Monopar Therapeutics

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/12/26

Business Summary

Monopar Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics for unmet medical needs. It generates value by advancing drug candidates through clinical trials with the goal of regulatory approval and eventual commercialization or partnership. Cash flow today is not driven by product sales but by capital raised and strategic funding to support R&D programs. Its competitive moat, if realized, would come from intellectual property protection around successful drug candidates and the pricing power that accompanies approved specialty therapeutics.

 


Analyze MNPR on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$375

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

2.7

EV / EBITDA

-14.10

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.85

Next Year EPS Growth Estimate

-$3.73

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-9.90%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

3

Altman Z-Score

77.7

Return on Invested Capital (ROIC)

-17.30%

Current Ratio

51.4

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze MNPR on TradingView

Gainseekers Quantitative Analysis

Summary

This is a highly speculative balance-sheet-driven story masquerading as a growth equity. With no P/E, no Forward P/E, and a negative EPS of -14.10, the company is not currently valued on earnings power but on optionality. The Altman Z-Score of 77.7 is extraordinarily strong, signaling minimal near-term bankruptcy risk, reinforced by a massive 51.4 current ratio. However, with ROIC at -17.30% and operating margins at -9.90%, capital is being destroyed, not compounded. The market is not mispricing stability—it is pricing binary biotech uncertainty, and without forward profitability metrics, there is no evidence of scalable earnings inflection.

AI Exposure / Tech Reliance

As a biotechnology company in Healthcare, Monopar operates in a sector increasingly shaped by AI-driven drug discovery and clinical data optimization. While no direct AI metrics are provided, biotech as an industry benefits structurally from computational acceleration in molecule screening and trial analytics. Its ability to remain relevant will depend on how efficiently it converts R&D into viable therapeutics rather than on legacy infrastructure.

The Bull Case

A deep value or speculative GARP investor could justify a position based almost entirely on balance sheet strength and survivability. The 51.4 current ratio and extraordinary 77.7 Altman Z-Score indicate overwhelming liquidity and negligible insolvency risk, giving the company time to execute. Institutional ownership at 112.78% suggests strong professional participation, often a signal that sophisticated investors see embedded optionality. While ROIC is -17.30% and the Piotroski F-Score is a weak 3, these are typical of development-stage biotech firms before commercialization inflection. At a $375M market cap with no leverage metrics flagged and a Price/Book of 2.7, investors are effectively paying for pipeline probability rather than current earnings, and that asymmetry can be attractive if clinical milestones materialize.

The Bear Case

The bear case is blunt: this is a capital-consuming biotech with negative earnings of -14.10, negative ROIC of -17.30%, and operating margins of -9.90%, meaning there is no underlying profitability engine. There is no P/E, no Forward P/E, and no PEG ratio provided, underscoring the absence of measurable earnings visibility. Sales Growth Next Year is listed as -$3.73, signaling contraction rather than expansion. A Piotroski F-Score of 3 indicates weak fundamental momentum, and with no dividend, no yield, and no payout, shareholders rely entirely on capital gains from uncertain drug development outcomes.

Market Sentiment & Smart Money

Short Interest %

65.80%

Analyst Consensus

1.2

Average Analyst Price Target

$112.78

Institutional Ownership %

83.20%

1-Year Beta

1.28

Insider Buying % (6 Mo)

23.70%%

Distance to 52-Week High

53.40%

Distance to 52-Week Low

197.50%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.